Safety of high-dose-rate stereotactic body radiotherapy

Radiation Oncology

Oliver Riesterer¹  Shaun Graydon¹  Claudia Linsenmeier¹  Stephanie Lang¹  Sonja Stieb¹ 

[1]Department of Radiation Oncology, University Hospital Zurich, Rämistrasse 100, Zurich, 8091, Switzerland

关键词: Toxicity;    Dose rate;    Stereotactic ablative radiotherapy (SABR);    Stereotactic body radiotherapy (SBRT);    Flattening filter free;   

Others  :  1149845
DOI  :  10.1186/s13014-014-0317-0

 received in 2014-10-10, accepted in 2014-12-21,  发布年份 2015

【 摘 要 】

Background and purpose

Flattening filter free (FFF) beams with high dose rate are increasingly used for stereotactic body radiotherapy (SBRT), because they substantially shorten beam-on time. The physical properties of these beams together with potentially unknown radiobiological effects might affect patient safety. Therefore here we analyzed the clinical outcome of our patients.

Material and methods

Between 3/2010 and 2/2014 84 patients with 100 lesions (lung 75, liver 10, adrenal 6, lymph nodes 5, others 4) were treated with SBRT using 6 MV FFF or 10 MV FFF beams at our institution. Clinical efficacy endpoints and toxicity were assessed by Kaplan-Meier analysis and CTCAE criteria version 4.0.

Results

Median follow-up was 11 months (range: 3–41). No severe acute toxicity was observed. There has been one case of severe late toxicity (1%), a grade 3 bile duct stricture that was possibly related to SBRT. For all patients, the 1-year local control rate, progression free survival and overall survival were 94%, 38% and 80% respectively, and for patients with lung lesions 94%, 48% and 83%, respectively.

Conclusions

No unexpected toxicity occurred. Toxicity and treatment efficacy are perfectly in range with studies investigating SBRT with flattened beams. The use of FFF beams at maximum dose rate for SBRT is time efficient and appears to be safe.

【 授权许可】

   
2015 Stieb et al. ; licensee BioMed Central.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Hrbacek J, Lang S, Klock S. Commissioning of photon beams of a flattening filter-free linear accelerator and the accuracy of beam modeling using an anisotropic analytical algorithm. Int J Radiat Oncol Biol Phys. 2011; 80:1228-1237.
• [2]Lang S, Shrestha B, Graydon S, Cavelaars F, Linsenmeier C, Hrbacek J, Klock S, Studer G, Riesterer O. Clinical application of flattening filter free beams for extracranial stereotactic radiotherapy. Radiother Oncol. 2013; 106:255-259.
• [3]Mancosu P, Castiglioni S, Reggiori G, Catalano M, Alongi F, Pellegrini C, Arcangeli S, Tozzi A, Lobefalo F, Fogliata A, Navarria P, Cozzi L, Scorsetti M. Stereotactic body radiation therapy for liver tumours using flattening filter free beam: dosimetric and technical considerations. Radiat Oncol. 2012; 7:16. BioMed Central Full Text
• [4]Reggiori G, Mancosu P, Castiglioni S, Alongi F, Pellegrini C, Lobefalo F, Catalano M, Fogliata A, Arcangeli S, Navarria P, Cozzi L, Scorsetti M. Can volumetric modulated arc therapy with flattening filter free beams play a role in stereotactic body radiotherapy for liver lesions? A volume-based analysis. Med Phys. 2012; 39:1112-1118.
• [5]Ong CL, Dahele M, Cuijpers JP, Senan S, Slotman BJ, Verbakel WF. Dosimetric impact of intrafraction motion during RapidArc stereotactic vertebral radiation therapy using flattened and flattening filter-free beams. Int J Radiat Oncol Biol Phys. 2013; 86:420-425.
• [6]Karan T, Moiseenko V, Gill B, Horwood R, Kyle A, Minchinton AI. Radiobiological effects of altering dose rate in filter-free photon beams. Phys Med Biol. 2013; 58:1075-1082.
• [7]King RB, Hyland WB, Cole AJ, Butterworth KT, McMahon SJ, Redmond KM, Trainer C, Prise KM, McGarry CK, Hounsell AR. An in vitro study of the radiobiological effects of flattening filter free radiotherapy treatments. Phys Med Biol. 2013; 58:N83-94.
• [8]Sorensen BS, Vestergaard A, Overgaard J, Praestegaard LH. Dependence of cell survival on instantaneous dose rate of a linear accelerator. Radiother Oncol. 2011; 101:223-225.
• [9]Verbakel WF, van den Berg J, Slotman BJ, Sminia P. Comparable cell survival between high dose rate flattening filter free and conventional dose rate irradiation. Acta Oncol. 2013; 52:652-657.
• [10]Lohse I, Lang S, Hrbacek J, Scheidegger S, Bodis S, Macedo NS, Feng J, Lutolf UM, Zaugg K. Effect of high dose per pulse flattening filter-free beams on cancer cell survival. Radiother Oncol. 2011; 101:226-232.
• [11]Favaudon V, Caplier L, Monceau V, Pouzoulet F, Sayarath M, Fouillade C, Poupon MF, Brito I, Hupe P, Bourhis J, Hall J, Fontaine JJ, Vozenin MC. Ultrahigh dose-rate FLASH irradiation increases the differential response between normal and tumor tissue in mice. Sci Transl Med. 2014; 6:245ra293.
• [12]Ling CC, Gerweck LE, Zaider M, Yorke E. Dose-rate effects in external beam radiotherapy redux. Radiother Oncol. 2010; 95:261-268.
• [13]Hrbacek J, Lang S, Graydon SN, Klock S, Riesterer O. Dosimetric comparison of flattened and unflattened beams for stereotactic ablative radiotherapy of stage I non-small cell lung cancer. Med Phys. 2014; 41:031709.
• [14]Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009; 45:228-247.
• [15]Guckenberger M, Klement RJ, Allgauer M, Appold S, Dieckmann K, Ernst I, Ganswindt U, Holy R, Nestle U, Nevinny-Stickel M, Semrau S, Sterzing F, Wittig A, Andratschke N, Flentje M. Applicability of the linear-quadratic formalism for modeling local tumor control probability in high dose per fraction stereotactic body radiotherapy for early stage non-small cell lung cancer. Radiother Oncol. 2013; 109:13-20.
• [16]Guckenberger M, Wulf J, Mueller G, Krieger T, Baier K, Gabor M, Richter A, Wilbert J, Flentje M. Dose-response relationship for image-guided stereotactic body radiotherapy of pulmonary tumors: relevance of 4D dose calculation. Int J Radiat Oncol Biol Phys. 2009; 74:47-54.
• [17]Kestin L, Grills I, Guckenberger M, Belderbos J, Hope AJ, Werner-Wasik M, Sonke JJ, Bissonnette JP, Xiao Y, Yan D. Dose-response relationship with clinical outcome for lung stereotactic body radiotherapy (SBRT) delivered via online image guidance. Radiother Oncol. 2014; 110:499-504.
• [18]Onishi H, Araki T, Shirato H, Nagata Y, Hiraoka M, Gomi K, Yamashita T, Niibe Y, Karasawa K, Hayakawa K, Takai Y, Kimura T, Hirokawa Y, Takeda A, Ouchi A, Hareyama M, Kokubo M, Hara R, Itami J, Yamada K. Stereotactic hypofractionated high-dose irradiation for stage I nonsmall cell lung carcinoma: clinical outcomes in 245 subjects in a Japanese multiinstitutional study. Cancer. 2004; 101:1623-1631.
• [19]Rusthoven KE, Kavanagh BD, Cardenes H, Stieber VW, Burri SH, Feigenberg SJ, Chidel MA, Pugh TJ, Franklin W, Kane M, Gaspar LE, Schefter TE. Multi-institutional phase I/II trial of stereotactic body radiation therapy for liver metastases. J Clin Oncol. 2009; 27:1572-1578.
• [20]Wulf J, Baier K, Mueller G, Flentje MP. Dose-response in stereotactic irradiation of lung tumors. Radiother Oncol. 2005; 77:83-87.
• [21]Boda-Heggemann J, Mai S, Fleckenstein J, Siebenlist K, Simeonova A, Ehmann M, Steil V, Wenz F, Lohr F, Stieler F. Flattening-filter-free intensity modulated breath-hold image-guided SABR (Stereotactic ABlative Radiotherapy) can be applied in a 15-min treatment slot. Radiother Oncol. 2013; 109:505-509.
• [22]Kragl G, af Wetterstedt S, Knausl B, Lind M, McCavana P, Knoos T, McClean B, Georg D. Dosimetric characteristics of 6 and 10MV unflattened photon beams. Radiother Oncol. 2009; 93:141-146.
• [23]Lechner W, Palmans H, Solkner L, Grochowska P, Georg D. Detector comparison for small field output factor measurements in flattening filter free photon beams. Radiother Oncol. 2013; 109:356-360.
• [24]Stieler F, Fleckenstein J, Simeonova A, Wenz F, Lohr F. Intensity modulated radiosurgery of brain metastases with flattening filter-free beams. Radiother Oncol. 2013; 109:448-451.
• [25]Zwahlen DR, Lang S, Hrbacek J, Glanzmann C, Kloeck S, Najafi Y, Streller T, Studer G, Zaugg K, Luetolf UM. The use of photon beams of a flattening filter-free linear accelerator for hypofractionated volumetric modulated arc therapy in localized prostate cancer. Int J Radiat Oncol Biol Phys. 2012; 83:1655-1660.
• [26]Alongi F, Cozzi L, Arcangeli S, Iftode C, Comito T, Villa E, Lobefalo F, Navarria P, Reggiori G, Mancosu P, Clerici E, Fogliata A, Tomatis S, Taverna G, Graziotti P, Scorsetti M. Linac based SBRT for prostate cancer in 5 fractions with VMAT and flattening filter free beams: preliminary report of a phase II study. Radiat Oncol. 2013; 8:171. BioMed Central Full Text
• [27]Alongi F, Fogliata A, Clerici E, Navarria P, Tozzi A, Comito T, Ascolese AM, Clivio A, Lobefalo F, Reggiori G, Cozzi L, Mancosu P, Tomatis S, Scorsetti M. Volumetric modulated arc therapy with flattening filter free beams for isolated abdominal/pelvic lymph nodes: report of dosimetric and early clinical results in oligometastatic patients. Radiat Oncol. 2012; 7:204. BioMed Central Full Text
• [28]Navarria P, Ascolese AM, Mancosu P, Alongi F, Clerici E, Tozzi A, Iftode C, Reggiori G, Tomatis S, Infante M, Alloisio M, Testori A, Fogliata A, Cozzi L, Morenghi E, Scorsetti M. Volumetric modulated arc therapy with flattening filter free (FFF) beams for stereotactic body radiation therapy (SBRT) in patients with medically inoperable early stage non small cell lung cancer (NSCLC). Radiother Oncol. 2013; 107:414-418.
• [29]Prendergast BM, Dobelbower MC, Bonner JA, Popple RA, Baden CJ, Minnich DJ, Cerfolio RJ, Spencer SA, Fiveash JB. Stereotactic body radiation therapy (SBRT) for lung malignancies: preliminary toxicity results using a flattening filter-free linear accelerator operating at 2400 monitor units per minute. Radiat Oncol. 2013; 8:273. BioMed Central Full Text
• [30]Scorsetti M, Alongi F, Castiglioni S, Clivio A, Fogliata A, Lobefalo F, Mancosu P, Navarria P, Palumbo V, Pellegrini C, Pentimalli S, Reggiori G, Ascolese AM, Roggio A, Arcangeli S, Tozzi A, Vanetti E, Cozzi L. Feasibility and early clinical assessment of flattening filter free (FFF) based stereotactic body radiotherapy (SBRT) treatments. Radiat Oncol. 2011; 6:113. BioMed Central Full Text
• [31]Wang PM, Hsu WC, Chung NN, Chang FL, Jang CJ, Fogliata A, Scorsetti M, Cozzi L. Feasibility of stereotactic body radiation therapy with volumetric modulated arc therapy and high intensity photon beams for hepatocellular carcinoma patients. Radiat Oncol. 2014; 9:18. BioMed Central Full Text
• [32]Guckenberger M, Allgauer M, Appold S, Dieckmann K, Ernst I, Ganswindt U, Holy R, Nestle U, Nevinny-Stickel M, Semrau S, Sterzing F, Wittig A, Andratschke N. Safety and efficacy of stereotactic body radiotherapy for stage 1 non-small-cell lung cancer in routine clinical practice: a patterns-of-care and outcome analysis. J Thorac Oncol. 2013; 8:1050-1058.
• [33]Klement RJ, Allgauer M, Appold S, Dieckmann K, Ernst I, Ganswindt U, Holy R, Nestle U, Nevinny-Stickel M, Semrau S, Sterzing F, Wittig A, Andratschke N, Guckenberger M. Support vector machine-based prediction of local tumor control after stereotactic body radiation therapy for early-stage non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 2014; 88:732-738.
• [34]Baumann P, Nyman J, Hoyer M, Gagliardi G, Lax I, Wennberg B, Drugge N, Ekberg L, Friesland S, Johansson KA, Lund JS, Morhed E, Nilsson K, Levin N, Paludan M, Sederholm C, Traberg A, Wittgren L, Lewensohn R. Stereotactic body radiotherapy for medically inoperable patients with stage I non-small cell lung cancer - a first report of toxicity related to COPD/CVD in a non-randomized prospective phase II study. Radiother Oncol. 2008; 88:359-367.
• [35]Ong CL, Palma D, Verbakel WF, Slotman BJ, Senan S. Treatment of large stage I-II lung tumors using stereotactic body radiotherapy (SBRT): planning considerations and early toxicity. Radiother Oncol. 2010; 97:431-436.
• [36]Stauder MC, Macdonald OK, Olivier KR, Call JA, Lafata K, Mayo CS, Miller RC, Brown PD, Bauer HJ, Garces YI. Early pulmonary toxicity following lung stereotactic body radiation therapy delivered in consecutive daily fractions. Radiother Oncol. 2011; 99:166-171.